A bedside framework for antiplatelet selection in acute coronary syndromes: aspirin plus a P2Y12 inhibitor, PCI context, bleeding risk, oral absorption, drug interactions and when clopidogrel is favored over more potent agents.
Understand aspirin + P2Y12 dual-antiplatelet therapy as the default ACS pharmacologic backbone when bleeding risk permits.
Choose ticagrelor versus clopidogrel by PCI strategy, bleeding risk, need for oral anticoagulation, interactions and tolerance.
Recognize that shock, vomiting, ileus and opioid exposure can make oral platelet inhibition less predictable.
Integrate DAPT with anticoagulation and procedural bleeding risk rather than treating each drug in isolation.
Avoid reflexive long-duration triple therapy when a shorter aspirin course is indicated in patients requiring chronic anticoagulation.
Full ACS diagnosis, reperfusion and shock pathway.
Integrate anticoagulants, reversal and bleeding management.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: Irreversible COX-1 platelet inhibition and foundational antiplatelet therapy in ACS.
Monitor: Bleeding, hemoglobin, allergy history and procedural plan.
ICU role: Potent reversible oral P2Y12 inhibitor used in many PCI-treated ACS patients.
Monitor: Bleeding, dyspnea, heart rate, interacting drugs and adherence.
ICU role: Irreversible oral P2Y12 inhibitor with less potent/more variable platelet inhibition but important bleeding and anticoagulation niches.
Monitor: Bleeding, ischemic events, drug interactions and adherence.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Aspirin Antiplatelet agent | Irreversible COX-1 platelet inhibition and foundational antiplatelet therapy in ACS. | ✓ Give early in suspected type-1 ACS unless a true contraindication or active major bleeding changes the balance. | ✕ GI/intracranial bleeding, hypersensitivity and perioperative timing; it is not a substitute for reperfusion. | Bleeding, hemoglobin, allergy history and procedural plan. |
| Ticagrelor Reversible P2Y12 inhibitor | Potent reversible oral P2Y12 inhibitor used in many PCI-treated ACS patients. | ✓ Often preferred over clopidogrel for ACS patients undergoing PCI when bleeding risk and interactions permit. | ✕ Dyspnea, bradyarrhythmia, bleeding and CYP3A interactions; twice-daily adherence matters. | Bleeding, dyspnea, heart rate, interacting drugs and adherence. |
| Clopidogrel P2Y12 inhibitor | Irreversible oral P2Y12 inhibitor with less potent/more variable platelet inhibition but important bleeding and anticoagulation niches. | ✓ Useful when ticagrelor/prasugrel are unsuitable and commonly preferred as the P2Y12 agent when long-term oral anticoagulation must continue after PCI. | ✕ CYP2C19 loss-of-function/interaction can reduce effect; oral absorption may be unreliable in shock. | Bleeding, ischemic events, drug interactions and adherence. |
Why: Antiplatelets reduce thrombotic events but do not replace urgent reperfusion.
Why: Bleeding rises substantially when aspirin, P2Y12 inhibition and anticoagulation are stacked.
Why: Critical illness and opioid-related gastric stasis can delay enteral drug delivery.
Why: The timing of PCI/stent and bleeding severity determine the risk tradeoff.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
STEMI with no active bleeding and immediate PCI planned.
Use aspirin plus an appropriate P2Y12 inhibitor while prioritizing reperfusion.
NSTEMI after PCI with prior recurrent GI bleeding.
Use guideline-supported bleeding-reduction strategies rather than assuming 12 months of full-intensity DAPT is mandatory.
ACS patient on apixaban undergoes PCI.
Avoid prolonged triple therapy; coordinate a short aspirin course and P2Y12 strategy, commonly clopidogrel, with the ongoing anticoagulant.
Cardiogenic shock, morphine exposure and gastric ileus after oral P2Y12 load.
Do not assume immediate platelet inhibition; discuss absorption/timing and PCI strategy with cardiology/pharmacy.
Three days after PCI the patient develops life-threatening GI hemorrhage.
Treat hemorrhage and obtain urgent cardiology/GI input because complete antiplatelet interruption carries very high early stent-thrombosis risk; the plan must be individualized.
Irreversible platelet COX-1 inhibitor central to ACS and selected stroke pathways, with important ICU bleeding and peri-procedural implications.
Oral irreversible P2Y12 inhibitor used in ACS, PCI and short-course DAPT after selected minor stroke/high-risk TIA.
Potent reversible P2Y12 inhibitor used in ACS, with dyspnea/bradyarrhythmia and drug-interaction considerations.
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.